We have established an integrated set of core technologies for the discovery of drugs that act upon targets.

Key elements of our discovery technology include

1) Cross high throughput screening of human protein chips, which express hundreds of human genes that possible act as drug targets, with our unique target focused chemistry libraries, which contains over 180,000 compounds;

2) Proprietary computational chemistry methods; an extensive database, which integrates biological and chemical information about our targets and compounds;

3) An extensive intellectual property portfolio consisting of publications and patents applications in both China and United states.

By integrating a number of scientific and drug development disciplines, we are able to efficiently discover and develop small molecule compounds, and therefore have a reduced likelihood of adverse side effects and clinical failure.